{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T21:28:22Z","timestamp":1710451702454},"reference-count":83,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,11,13]],"date-time":"2007-11-13T00:00:00Z","timestamp":1194912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drug Reviews"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Chemically, TDIQ (5,6,7,8\u2013tetrahydro\u20101,3\u2010dioxolo[4,5\u2010<jats:italic>g<\/jats:italic>]isoquinoline) can be viewed as a conformationally restricted phenylalkylamine that is related in structure to amphetamine but does not stimulate (or depress) locomotor activity in rodents. In radioligand binding studies TDIQ displays selective affinity for \u03b1<jats:sub>2<\/jats:sub>\u2010adrenergic receptor subsites (i.e., \u03b1<jats:sub>2A<\/jats:sub>\u2010, \u03b1<jats:sub>2B<\/jats:sub>\u2010, and \u03b1<jats:sub>2C<\/jats:sub>\u2010adrenergic receptors), and behavioral data suggest that it might exert an agonist (or partial agonist) effect at \u03b1<jats:sub>2<\/jats:sub>\u2010adrenergic receptors or interact at \u03b1<jats:sub>2<\/jats:sub>\u2010adrenergic heteroreceptors. Drug discrimination studies in rats indicate that TDIQ: (1) serves as a discriminative stimulus, (2) may be useful in the treatment of symptoms associated with the abuse of cocaine, and (3) exhibits a low potential for abuse. In addition, TDIQ exhibits a dose\u2010dependent and wide dissociation between doses that produce an anxiolytic\u2010like effect or an inhibition of \u201csnack\u201d consumption in mice and doses that produce minimal, if any, effects in tests that measure a potential for disruption of coordinated movement or motor activity. Also, TDIQ displays negligible effects on the heart rate (HR) and blood pressure (BP) of mice. Taken together, the preclinical data suggest that TDIQ exhibits a favorable ratio of therapeutic\u2010like effects (anxiolytic, therapeutic adjunct in the treatment of cocaine abuse, and appetite suppression) to side effect\u2010like activities (behavioral impairment, drug abuse, or adverse cardiovascular effect). As such, TDIQ could: (1) be a forerunner for a new type of chemical entity in the treatment of certain forms of anxiety and\/or obesity and (2) serve as a structural template in the discovery and development of additional agents that might be selective for \u03b1<jats:sub>2<\/jats:sub>\u2010adrenergic receptors.<\/jats:p>","DOI":"10.1111\/j.1527-3458.2007.00022.x","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T01:20:26Z","timestamp":1195176026000},"page":"405-422","source":"Crossref","is-referenced-by-count":1,"title":["TDIQ (5,6,7,8\u2013tetrahydro\u20101,3\u2010dioxolo [4,5\u2010<i>g<\/i>]isoquinoline): Discovery, Pharmacological Effects, and Therapeutic Potential"],"prefix":"10.1111","volume":"13","author":[{"given":"Richard","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,13]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00413-4"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830050084013"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00140-7"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(80)90187-2"},{"key":"e_1_2_13_6_1","first-page":"343","article-title":"Lack of efficacy of yohimbine in the treatment of obesity","volume":"17","author":"Berlin I","year":"1986","journal-title":"J Pharmacol"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(03)00143-7"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.0.CO;2-J"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(86)90051-8"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00255-1"},{"key":"e_1_2_13_11_1","first-page":"121","article-title":"International Union of Pharmacology nomenclature of adrenoceptors","volume":"46","author":"Bylund DB","year":"1994","journal-title":"Pharmacol Rev"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00692-9"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00040-4"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(98)00127-0"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90478-X"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(02)00274-6"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00682-7"},{"key":"e_1_2_13_18_1","first-page":"179","volume-title":"Serotonin, CNS receptors and brain function","author":"Dourish CT","year":"1993"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(79)90211-5"},{"key":"e_1_2_13_20_1","first-page":"21","volume-title":"Textbook of Substance Abuse Treatment","author":"Fischman MW","year":"1999"},{"key":"e_1_2_13_21_1","first-page":"844","volume-title":"Physiol Rev","author":"Foote SL","year":"1983"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000046924.94886.EF"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.2307\/3583736"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200112000-00001"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.2610030305"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90488-2"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00768-7"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00217a019"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90578-3"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01361876"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.65010111.x"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1997.273.5.R1580"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00379-2"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.23.2847"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1988.tb08559.x"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780360094011"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(91)90073-X"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.01.005"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-020588-5.50019-9"},{"key":"e_1_2_13_40_1","first-page":"550","article-title":"Does yohimbine act as a slimming drug?","volume":"27","author":"Kucio C","year":"1991","journal-title":"Isr J Med Sci"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300428"},{"key":"e_1_2_13_42_1","first-page":"831","article-title":"Comparaison pharmacologique de sept m\u00e9dicaments anorexig\u00e8nes","volume":"19","author":"Le Douarec JC","year":"1964","journal-title":"Th\u00e9rapie"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(80)91037-9"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(85)90416-2"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2003.08.009"},{"key":"e_1_2_13_46_1","first-page":"S3","article-title":"The importance of rat models in hypertensive research","volume":"4","author":"Lovenberg W","year":"1986","journal-title":"J Hypertens"},{"key":"e_1_2_13_47_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0165-6147(97)90625-8","article-title":"Gene targeting\u2014homing in on \u03b12\u2010 adrenoceptor\u2010subtype function","volume":"18","author":"MacDonald E","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"e_1_2_13_48_1","first-page":"400","article-title":"1,2,3,4\u2010Tetrahydroisoquinoline analogs of phenylalkylamine stimulants and hallucinogens","volume":"6","author":"Malmusi L","year":"1996","journal-title":"Med Chem Res"},{"key":"e_1_2_13_49_1","first-page":"412","article-title":"1,2,3,4\u2010Tetrahydroisoquinolines and related analogs of the phenylalkylamine designer drug MDMA","volume":"6","author":"Malmusi L","year":"1996","journal-title":"Med Chem Res"},{"key":"e_1_2_13_50_1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1152\/ajplegacy.1975.229.6.1547","article-title":"Evoked release of [14C]norepinephrine from the rat hypothalamus during feeding","volume":"229","author":"Martin GE","year":"1975","journal-title":"Am J Physiol"},{"key":"e_1_2_13_51_1","first-page":"36","volume-title":"Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials","author":"McCance EF","year":"1997"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950090045007"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060010-00001"},{"key":"e_1_2_13_54_1","first-page":"1192","article-title":"S18616, a highly potent, spiroimidazoline agonist at \u03b12\u2010adrenoceptors: I","volume":"295","author":"Millan MJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(98)00725-2"},{"key":"e_1_2_13_56_1","first-page":"1187","article-title":"Discrimination and pharmacological characterization of I2\u2010imidazoline sites with [3H]RX821002(2\u2010methoxyidazoxan) in the human and rat brain","volume":"264","author":"Miralles A","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005243"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90478-7"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90590-X"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(86)90224-8"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90087-0"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1997.273.5.R1569"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.08.061"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.08.054"},{"key":"e_1_2_13_65_1","first-page":"561","article-title":"Yohimbine does not affect fat distribution in men","volume":"15","author":"Sax L","year":"1991","journal-title":"Int J Obes"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.12.1625"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703882"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(94)90386-7"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1997.tb48274.x"},{"key":"e_1_2_13_70_1","first-page":"397","volume-title":"Meyler's Side Effects of Drugs: An Encyclopedia of Adverse Reactions and Interactions","author":"Steiner JA","year":"1988"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.29.171"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00165728"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00178202"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173016"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005133"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00130-6"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(00)00415-9"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00436094"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.2610060105"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00666-9"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(99)00060-X"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2005.09.010"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2006.04.006"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2006.04.007"}],"container-title":["CNS Drug Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-3458.2007.00022.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-3458.2007.00022.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:44:58Z","timestamp":1697424298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-3458.2007.00022.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,13]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1527-3458.2007.00022.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-3458.2007.00022.x","archive":["Portico"],"relation":{},"ISSN":["1080-563X","1527-3458"],"issn-type":[{"value":"1080-563X","type":"print"},{"value":"1527-3458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,13]]}}}